Get the Stockscreener App
18.61
5.14%
0.91
10 X Genomics Inc stock is traded at $18.61, with a volume of 3.23M.
It is up +5.14% in the last 24 hours and down -3.63% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
See More
Previous Close:
$17.70
Open:
$18.32
24h Volume:
3.23M
Relative Volume:
1.22
Market Cap:
$2.36B
Revenue:
$631.73M
Net Income/Loss:
$-239.78M
P/E Ratio:
-9.2129
EPS:
-2.02
Net Cash Flow:
$-33.45M
1W Performance:
-7.87%
1M Performance:
-3.63%
6M Performance:
+47.00%
1Y Performance:
+27.03%
1-Day Range:
$17.70
$18.71
1-Week Range:
$17.37
$20.48
52-Week Range:
$6.78
$23.56
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, TEM, BTSG, HQY, DOCS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
18.61 | 2.24B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
183.65 | 30.22B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
54.91 | 9.33B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
BTSG
Brightspring Health Services Inc
|
39.68 | 6.92B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
79.45 | 6.77B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
27.73 | 6.27B | 550.17M | 201.35M | 232.07M | 1.00 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-11-25 | Initiated | Piper Sandler | Neutral |
| Feb-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch - MSN
Best Genetic Sequencing Stocks to Buy in 2026 and How to Invest in Them - The Motley Fool
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Finviz
PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology - PR Newswire
Fundamentals Check: Can 10x Genomics Inc sustain its profitabilityBull Run & Daily Profit Focused Screening - baoquankhu1.vn
Foundations Investment Advisors LLC Takes Position in 10x Genomics $TXG - MarketBeat
10x Genomics $TXG Holdings Decreased by Federated Hermes Inc. - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Purchases New Shares in 10x Genomics $TXG - MarketBeat
AlphaQuest LLC Increases Holdings in 10x Genomics $TXG - MarketBeat
Is 10x Genomics Inc. still a buy after recent gainsPortfolio Profit Report & AI Enhanced Trading Signals - Mfd.ru
Stock Report: Will 10x Genomics Inc. outperform its industry peersJuly 2025 Rallies & Expert Approved Momentum Ideas - mfd.ru
Breaking Down 10x Genomics: 13 Analysts Share Their Views - Benzinga
10x Genomics (NASDAQ:TXG) Given New $20.00 Price Target at Leerink Partners - MarketBeat
10x Genomics, Inc. (NASDAQ:TXG) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected - simplywall.st
Volume Report: How does 10x Genomics Inc perform in inflationary periods2025 Price Action Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - BioSpace
10x Genomics Expands Clinical Ambitions As Momentum Outruns Analyst Targets - simplywall.st
10x Genomics to Report Fourth Quarter and Full Year 2025 Financi - GuruFocus
Zacks Industry Outlook Highlights Doximity, 10x Genomics and Omnicell - Yahoo Finance
Revenue Check: What is VERX s P E ratio telling usAnalyst Upgrade & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Inscription Capital LLC Acquires 59,305 Shares of 10x Genomics $TXG - MarketBeat
10x Genomics (NASDAQ:TXG) Trading Up 8%Still a Buy? - MarketBeat
10x Genomics Inc (TXG) Trading 6.38% Higher on Jan 20 - GuruFocus
10X Genomics stock hits 52-week high of 21.52 USD - Investing.com
Cathie Wood's Ark Unleashes Cryptic ARKmoji Teasers To Showcase Its 'Big Ideas' For 2026: Can You Take A Guess At The Hidden Meaning? - Benzinga
Sentiment Recap: Is 10x Genomics Inc a strong candidate for buy and hold2025 Momentum Check & Real-Time Buy Signal Alerts - baoquankhu1.vn
Aug Breakouts: Is United States Steel Corporation stock a good pick for beginnersQuarterly Growth Report & Capital Protection Trade Alerts - baoquankhu1.vn
Aug Ideas: Can 10x Genomics Inc stock outperform in a bear marketJuly 2025 Closing Moves & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Did 10x Genomics’ (TXG) Clinical Collaborations and CLIA Push Just Recast Its Investment Narrative? - simplywall.st
Sumitomo Mitsui Trust Group Inc. Sells 636,744 Shares of 10x Genomics $TXG - MarketBeat
Aug Weekly: Whats the fair value of AN2 Therapeutics Inc stockWeekly Investment Summary & Technical Pattern Alert System - baoquankhu1.vn
Wall Street Recap: What is INTA s revenue forecastTrade Performance Summary & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Insider Trends: Will 10x Genomics Inc outperform its industry peersJuly 2025 Review & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Weak Instrument Sales And No 2026 Outlook Could Be A Game Changer For 10x Genomics (TXG) - Yahoo Finance
10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling - BioSpace
Analysts Offer Insights on Healthcare Companies: Stryker (SYK) and 10x Genomics (TXG) - The Globe and Mail
Why 10x Genomics (TXG) Shares Are Falling Today - Finviz
10x Genomics (NASDAQ:TXG) Shares Down 8.5%What's Next? - MarketBeat
Cancer Research Institute Launches Transformative AI-Driven Immu - GuruFocus
10x Genomics partners with Dana-Farber to research cancer treatment responses - Investing.com
10x Genomics partners with Brigham & Women’s for autoimmune research - Investing.com
10x Genomics partners with Brigham & Women’s for autoimmune research By Investing.com - Investing.com Canada
10x Genomics Launches Study to Advance Research in Blood-Based D - GuruFocus
10x Genomics to Advance Research in Diagnostic Applications of T - GuruFocus
10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease - PR Newswire
Cancer Research Institute Launches Transformative AI-Driven Immuno-Oncology Initiative Powered by 10x Genomics Technology - PR Newswire
10x Genomics (TXG) Sees Modest Q4 Growth Amid Revenue Challenges - GuruFocus
10x Genomics sees uptick in Q4 revenue despite softer FY sales (TXG:NASDAQ) - Seeking Alpha
10x Genomics (TXG) Achieves Remarkable Progress Despite Economic Challenges - GuruFocus
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results - The Malaysian Reserve
Revenues Not Telling The Story For 10x Genomics, Inc. (NASDAQ:TXG) After Shares Rise 32% - 富途牛牛
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.73%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):